vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and INTERGROUP CORP (INTG). Click either name above to swap in a different company.
INTERGROUP CORP is the larger business by last-quarter revenue ($17.3M vs $15.0M, roughly 1.2× CHAMPIONS ONCOLOGY, INC.). INTERGROUP CORP runs the higher net margin — 8.8% vs 1.8%, a 7.0% gap on every dollar of revenue. On growth, INTERGROUP CORP posted the faster year-over-year revenue change (19.8% vs 11.5%). INTERGROUP CORP produced more free cash flow last quarter ($-481.0K vs $-2.0M). Over the past eight quarters, CHAMPIONS ONCOLOGY, INC.'s revenue compounded faster (11.8% CAGR vs 7.8%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
Intergroup Corp is a diversified holding firm operating two core segments: real estate and hotel operations. It owns, manages and leases commercial and residential properties across the U.S., and runs limited-service hotels for leisure and business travelers.
CSBR vs INTG — Head-to-Head
Income Statement — Q2 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $17.3M |
| Net Profit | $268.0K | $1.5M |
| Gross Margin | 51.7% | — |
| Operating Margin | 1.2% | 11.6% |
| Net Margin | 1.8% | 8.8% |
| Revenue YoY | 11.5% | 19.8% |
| Net Profit YoY | -63.2% | 155.6% |
| EPS (diluted) | $0.02 | $0.71 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $17.3M | ||
| Q3 25 | $14.0M | $17.9M | ||
| Q2 25 | $12.4M | $16.2M | ||
| Q1 25 | $17.0M | $16.8M | ||
| Q4 24 | $13.5M | $14.4M | ||
| Q3 24 | $14.1M | $16.9M | ||
| Q2 24 | $14.0M | $13.4M | ||
| Q1 24 | $12.0M | $14.9M |
| Q4 25 | $268.0K | $1.5M | ||
| Q3 25 | $-436.0K | $-535.0K | ||
| Q2 25 | $-1.8M | $-2.2M | ||
| Q1 25 | $4.5M | $-578.0K | ||
| Q4 24 | $728.0K | $-2.7M | ||
| Q3 24 | $1.3M | $-398.0K | ||
| Q2 24 | $-109.0K | $-4.9M | ||
| Q1 24 | $-2.5M | $-3.2M |
| Q4 25 | 51.7% | — | ||
| Q3 25 | 42.9% | — | ||
| Q2 25 | 41.1% | — | ||
| Q1 25 | 61.2% | — | ||
| Q4 24 | 44.9% | — | ||
| Q3 24 | 49.7% | — | ||
| Q2 24 | 48.2% | — | ||
| Q1 24 | 34.7% | — |
| Q4 25 | 1.2% | 11.6% | ||
| Q3 25 | -3.8% | 15.3% | ||
| Q2 25 | -16.2% | 8.1% | ||
| Q1 25 | 26.4% | 14.0% | ||
| Q4 24 | 5.4% | 5.9% | ||
| Q3 24 | 9.5% | 18.5% | ||
| Q2 24 | -1.9% | 3.7% | ||
| Q1 24 | -21.4% | 4.8% |
| Q4 25 | 1.8% | 8.8% | ||
| Q3 25 | -3.1% | -3.0% | ||
| Q2 25 | -14.9% | -13.9% | ||
| Q1 25 | 26.4% | -3.4% | ||
| Q4 24 | 5.4% | -18.9% | ||
| Q3 24 | 9.3% | -2.4% | ||
| Q2 24 | -0.8% | -36.7% | ||
| Q1 24 | -21.1% | -21.3% |
| Q4 25 | $0.02 | $0.71 | ||
| Q3 25 | $-0.03 | $-0.25 | ||
| Q2 25 | $-0.12 | — | ||
| Q1 25 | $0.31 | $-0.27 | ||
| Q4 24 | $0.05 | $-1.26 | ||
| Q3 24 | $0.09 | $-0.18 | ||
| Q2 24 | $-0.01 | — | ||
| Q1 24 | $-0.19 | $-1.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $7.5M |
| Total DebtLower is stronger | — | $233.2M |
| Stockholders' EquityBook value | $4.2M | $-85.2M |
| Total Assets | $30.2M | $101.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $7.5M | ||
| Q3 25 | $10.3M | $6.0M | ||
| Q2 25 | $9.8M | $6.1M | ||
| Q1 25 | $3.2M | $4.8M | ||
| Q4 24 | $2.8M | $15.4M | ||
| Q3 24 | $2.9M | $12.2M | ||
| Q2 24 | $2.6M | $11.6M | ||
| Q1 24 | $4.5M | $19.5M |
| Q4 25 | — | $233.2M | ||
| Q3 25 | — | $237.8M | ||
| Q2 25 | — | $240.5M | ||
| Q1 25 | — | $241.5M | ||
| Q4 24 | — | $227.2M | ||
| Q3 24 | — | $218.1M | ||
| Q2 24 | — | $225.7M | ||
| Q1 24 | — | $225.0M |
| Q4 25 | $4.2M | $-85.2M | ||
| Q3 25 | $3.5M | $-86.7M | ||
| Q2 25 | $3.8M | $-86.1M | ||
| Q1 25 | $5.5M | $-84.5M | ||
| Q4 24 | $681.0K | $-83.9M | ||
| Q3 24 | $-332.0K | $-80.9M | ||
| Q2 24 | $-1.9M | $-80.3M | ||
| Q1 24 | $-2.1M | $-76.4M |
| Q4 25 | $30.2M | $101.1M | ||
| Q3 25 | $30.5M | $102.5M | ||
| Q2 25 | $32.3M | $104.1M | ||
| Q1 25 | $30.6M | $103.2M | ||
| Q4 24 | $25.2M | $110.6M | ||
| Q3 24 | $24.9M | $109.3M | ||
| Q2 24 | $26.1M | $107.8M | ||
| Q1 24 | $26.8M | $119.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $-23.0K |
| Free Cash FlowOCF − Capex | $-2.0M | $-481.0K |
| FCF MarginFCF / Revenue | -13.1% | -2.8% |
| Capex IntensityCapex / Revenue | 1.6% | 2.6% |
| Cash ConversionOCF / Net Profit | -6.47× | -0.02× |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | $739.0K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $-23.0K | ||
| Q3 25 | $600.0K | $-296.0K | ||
| Q2 25 | $6.9M | $5.9M | ||
| Q1 25 | $490.0K | $-854.0K | ||
| Q4 24 | $-283.0K | $-781.0K | ||
| Q3 24 | $311.0K | $3.4M | ||
| Q2 24 | $-1.8M | $6.8M | ||
| Q1 24 | $-919.0K | $1.9M |
| Q4 25 | $-2.0M | $-481.0K | ||
| Q3 25 | $554.0K | $-1.3M | ||
| Q2 25 | $6.6M | $3.6M | ||
| Q1 25 | $448.0K | $-1.2M | ||
| Q4 24 | $-377.0K | $-1.1M | ||
| Q3 24 | — | $3.1M | ||
| Q2 24 | $-1.8M | $2.7M | ||
| Q1 24 | $-1.0M | $1.1M |
| Q4 25 | -13.1% | -2.8% | ||
| Q3 25 | 4.0% | -7.1% | ||
| Q2 25 | 53.5% | 22.5% | ||
| Q1 25 | 2.6% | -6.8% | ||
| Q4 24 | -2.8% | -7.8% | ||
| Q3 24 | — | 18.3% | ||
| Q2 24 | -13.0% | 20.4% | ||
| Q1 24 | -8.4% | 7.6% |
| Q4 25 | 1.6% | 2.6% | ||
| Q3 25 | 0.3% | 5.4% | ||
| Q2 25 | 2.0% | 13.9% | ||
| Q1 25 | 0.2% | 1.8% | ||
| Q4 24 | 0.7% | 2.4% | ||
| Q3 24 | 0.0% | 1.6% | ||
| Q2 24 | 0.0% | 30.4% | ||
| Q1 24 | 0.8% | 4.9% |
| Q4 25 | -6.47× | -0.02× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | -0.39× | — | ||
| Q3 24 | 0.24× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
INTG
| Hotel Operations | $12.7M | 73% |
| Real Estate Operation | $4.6M | 27% |
